Results From a Nordic
Lymphoma Group Phase II Study.
Not exact matches
Dose - densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high - risk diffuse large B - cell / follicular grade 3
lymphoma patients: results of a phase II Nordic Lymphoma Grou
lymphoma patients: results of a
phase II Nordic
Lymphoma Grou
Lymphoma Group study.
The Nordic
Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age - adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance tr
Lymphoma Group has conducted a
phase ll trial in newly diagnosed primary central nervous system
lymphoma patients applying an age - adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance tr
lymphoma patients applying an age - adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance treatment.
Chemotherapy Alone as Initial Treatment for Primary CNS
Lymphoma in Patients Older Than 60 Years: A Multicenter
Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor
Group
Escalated BEACOPP Plus Rituximab in Advanced Hodgkin
Lymphoma Fails to Improve Outcomes: The results of the phase III HD18 trial by the German Hodgkin Study Group determined that the addition of rituximab to an escalated regimen of BEACOPP did not improve progression - free survival (PFS) in patients with advanced - stage Hodgkin l
Lymphoma Fails to Improve Outcomes: The results of the
phase III HD18 trial by the German Hodgkin Study
Group determined that the addition of rituximab to an escalated regimen of BEACOPP did not improve progression - free survival (PFS) in patients with advanced - stage Hodgkin
lymphomalymphoma.